Although researchers have previously always struggled to develop an efficient HIV vaccine, the results of a first-in-human clinical trial for a new vaccine appear promising. The new vaccine has been developed using a new design technique, which is being followed by researchers.
The research has been published in Science, after being undertaken by researchers at Scripps Research, IAVI, Fred Hutchinson Cancer Center (Fred Hutch), National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) and Vaccine Research Center (VCR). The research shows new insights into the novel vaccine strategy, including its approach to how it will produce antibodies to target various HIV variants.
